Page last updated: 2024-11-07

ci 949

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CI 949: antiallergic cpd; interleukin-1 and interleukin-2 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159562
SCHEMBL ID17041896
MeSH IDM0170076

Synonyms (13)

Synonym
ci 949
121530-58-3
unii-em1j51043x
em1j51043x ,
5-methoxy-3-(1-methylethoxy)-1-phenyl-n-1h-tetrazol-5-yl-1h-indole-2-carboxamide l-arginate salt
OHOCQQJBKBVAFF-VWMHFEHESA-N ,
SCHEMBL17041896
DTXSID90923850
arginine--5-methoxy-1-phenyl-3-[(propan-2-yl)oxy]-n-(2h-tetrazol-5-yl)-1h-indole-2-carboximidic acid (1/1)
ci-949 arginate
104961-35-5
5-methoxy-3-(1-methylethoxy)-1-phenyl-n-1h-tetrazol-5-yl-1h-indole-2-carboxamide arginine
(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;5-methoxy-1-phenyl-3-propan-2-yloxy-n-(2h-tetrazol-5-yl)indole-2-carboxamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's7 (77.78)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.52 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]